SUNPHARMA - Investment Analysis: Buy Signal or Bull Trap?
Back to ListInvestment Rating: 3.9
| Stock Code | SUNPHARMA | Market Cap | 4,37,543 Cr. | Current Price | 1,824 ₹ | High / Low | 1,849 ₹ |
| Stock P/E | 100 | Book Value | 99.2 ₹ | Dividend Yield | 0.88 % | ROCE | 16.8 % |
| ROE | 17.8 % | Face Value | 1.00 ₹ | DMA 50 | 1,728 ₹ | DMA 200 | 1,714 ₹ |
| Chg in FII Hold | -0.18 % | Chg in DII Hold | 0.28 % | PAT Qtr | 872 Cr. | PAT Prev Qtr | 564 Cr. |
| RSI | 64.6 | MACD | 10.7 | Volume | 44,68,829 | Avg Vol 1Wk | 90,57,018 |
| Low price | 1,547 ₹ | High price | 1,849 ₹ | PEG Ratio | 1.37 | Debt to equity | 0.56 |
| 52w Index | 91.6 % | Qtr Profit Var | -24.6 % | EPS | 16.7 ₹ | Industry PE | 30.2 |
📊 Analysis: Sun Pharma (SUNPHARMA) is a leading pharmaceutical company with a strong market cap of ₹4,37,543 Cr. The stock trades at a very high P/E of 100 compared to the industry average of 30.2, indicating overvaluation. ROE (17.8%) and ROCE (16.8%) are healthy, showing efficient capital use. However, EPS of ₹16.7 is modest relative to its valuation, and dividend yield of 0.88% is limited. The PEG ratio of 1.37 suggests fair but not cheap growth valuation. PAT rose sequentially (₹872 Cr vs ₹564 Cr), but quarterly profit variation (-24.6%) highlights volatility. Current price (₹1,824) is near its 52-week high (₹1,849), making entry less attractive at present levels.
💰 Entry Price Zone: Ideal accumulation range is ₹1,650–1,720, closer to the 50 DMA (₹1,728) and 200 DMA (₹1,714). Buying near these levels offers better value and reduces risk of entering at peak valuations.
📈 Exit / Holding Strategy: If already holding, maintain a long-term horizon (3–5 years) given strong fundamentals and industry leadership. Consider partial profit booking near ₹1,850–1,900 resistance levels. Retain core holdings for compounding growth, but monitor valuation risks closely.
✅ Positive
- Strong ROE (17.8%) and ROCE (16.8%)
- Low debt-to-equity ratio (0.56)
- Sequential PAT growth (₹872 Cr vs ₹564 Cr)
- Institutional confidence with DII holdings up (+0.28%)
⚠️ Limitation
- Extremely high P/E (100) vs industry average (30.2)
- Dividend yield (0.88%) is modest
- Quarterly profit variation (-24.6%) shows volatility
- EPS (₹16.7) is low relative to valuation
📉 Company Negative News
- FII holdings declined (-0.18%)
- Valuation stretched near 52-week high
📈 Company Positive News
- Sequential PAT growth indicates operational improvement
- DII holdings increased (+0.28%) showing domestic confidence
🏦 Industry
- Pharma sector trades at P/E of 30.2, much lower than Sun Pharma’s valuation
- Industry growth supported by global demand for generics and specialty drugs
🔎 Conclusion
Sun Pharma is a strong long-term candidate due to its leadership position, healthy ROE/ROCE, and consistent growth. However, current valuations are stretched. Entry around ₹1,650–1,720 is preferable. Long-term holders should stay invested for 3–5 years, booking profits near resistance levels while retaining core holdings for compounding growth.